Welcome to the Working Group on New TB Drugs Blog
Summary Available! TB Clinical Trials Consultants Meeting
On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.
TB R&D Weekly Update: Progress in Development of New TB Drugs
During last week, the Stop TB Partnership Working Group on New Drugs had a successful annual meeting in Lille, France, in conjunction with the 42nd Union World Conference. There were quite a few updates to the Global TB Drugs Pipeline showing progress toward the goal of better treatment for TB in all patient populations. Additional links to TB R&D news are included.
TB R&D Weekly Update: Zinc Used by Host to Fight TB
This week, we provide an brief overview of research supported by CNRS, INSERM, Institut Pasteur and other donors providing new evidence of the role of Zinc in the body’s immune response to intracellular infection by M.tb. and the microbe’s strategy to subvert this defense. Additional links to TB R&D news are included.
TB R&D Weekly Update: TB Drug Updates in Future Medicinal Chemistry
Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development. Additional links to TB R&D news are included.
TB R&D Weekly Update: Future Medicinal Chemistry Features Neglected Diseases
The August and September issues of Future Medicinal Chemistry will focus on neglected diseases including tuberculosis. The issue includes articles from TB researchers including Ann Ginsberg and Takushi Kaneko. Additional links to TB R&D news are included
Posted in Announcements, market access, TB News, TB Prevention and Control Strategies, TB Treatment, Video
Private TB Drug Market is Larger than Expected
The first detailed study of the private tuberculosis (TB) drug market, published on May 4th, in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-TB).
Posted in Announcements, Early Drug Development, Front Lines of TB R&D, TB Drug Development, TB News, TB Treatment
First Chinese Product Development Partnership for TB, Malaria and HIV/AIDS Announced
Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC), announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will focus on the development of treatments for the world’s leading infectious disease killers—tuberculosis, malaria, and HIV/AIDS.
TB R&D Weekly Update: Redefining Tuberculosis Immunopathology
In this week’s TB R&D update, we look at whether researchers should change their view and definitions of immunopathology in tuberculosis. The authors suggest that the term “caseous necrosis” should actually be split into three processes. The article is published in the February issue of Science Translational Medicine and is entitled “Tuberculosis immunopathology: the neglected role of extracellular matrix destruction.” Also, links to additional news in TB R&D are included.
WGND 2010 Annual Meeting: Panel Discussion
Following the guest speakers, several representatives from companies conducting clinical trials of TB drug candidates presented brief updates on progress made in the clinical development of their candidates. We recap the presentations here and offer .pdf downloads of the original presentations.
WGND 2010 Annual Meeting Recap
Thank you to everyone who was able to join us in Berlin. This recap summarizes the work that was presented at our Annual Meeting on November 12. Co-chairs of WGND, Mel Spigelmen and Bill Bishai opened the annual meeting by welcoming the attendees and briefly reviewing the agenda for the meeting.
-
Toppix TB News- Editorial: Lives at risk if the U.S. shortchanges Global Fund 4 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- WHO says TB in Russia displays highest known drug resistance 3 Feb 2012
- Media outlets examine Global Fund's future as it enters second decade 3 Feb 2012
